This patent includes composition of matter, pharmaceutical composition, method of treatment, and synthetic method claims directed to heat shock protein 90 (Hsp90) inhibitor and other hydroquinone-containing ansamycin analogues.
IPI-504, the companies’ lead Hsp90 inhibitor, is currently being evaluated in two separate multi-center clinical trials in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas, and in patients with non-small cell lung cancer. The patent is owned by Infinity and is co-exclusively licensed to MedImmune pursuant to the terms of the parties’ collaboration agreement.
Infinity and MedImmune also announced that the European Medicines Agency’s Committee for Orphan Medicinal Products has granted IPI-504 orphan drug designation for the treatment of GIST.